1883545-57-0
1883545-57-0
Chemical Structure
Miglustat-d9 hydrochloride
Synonym(s): N-Butyldeoxynojirimycin-d9 hydrochloride; NB-DNJ-d9 hydrochloride; OGT 918-d9 hydrochloride
- CAS No.: 1883545-57-0
- Formula:C10H13D9ClNO4
- Molecular Weight:264.79
IUPAC Name: (2R,3R,4R,5S)-1-(butyl-d9)-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride
InChIKey: QPAFAUYWVZMWPR-LQJTUGORSA-N
SMILES: O[C@H]1[C@@H]([C@H](N(C[C@@H]1O)C([2H])(C([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])[2H])CO)O.Cl
Biological Activity: Miglustat-d9 hydrochloride is the deuterium labeled Miglustat hydrochloride. Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Miglustat-d9 hydrochloride | 99.4% | Miglustat-d9 hydrochloride is the deuterium labeled Miglustat hydrochloride. Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Miglustat hydrochloride (Standard) | ≥98% | Miglustat (hydrochloride) (Standard) is the analytical standard of Miglustat (hydrochloride). This product is intended for research and analytical applications. Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Miglustat hydrochloride | 99.97% | Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor, with blood-brain barrier permeability. Miglustat hydrochloride can be used for the research of type I gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm, 2011. 8(6): p. 2390-7.;van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47(10): p. 1277-82. [Content Brief]
